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the evidence base. This evidence base was then investigated, in
order to assess ﬁndings to answer the study question. RESULTS:
In total, 52 papers were listed; four were relevant for inclusion.
two of these articles were retrospective cohort studies and two
were based on budget-impact models. Costs were presented as
medical charges; medication possession ratio (MPR) and/or per-
sistence rates were measures of non-compliance; osteoporosis
medications included bisphosphonates and HRT. US Medical
charges were 35% higher in non-compliers compared with
compliers and total monthly charges were 76% higher. Based
on modelling, persistence levels with bisphosphonates of <50%
at 12 months results in almost 20,000 excess fractures over a
10 year period and 22 M per annum fracture-related costs to
the UK NHS. CONCLUSION: The evidence base in this area is
limited. However, it indicates that medication non-compliance
and failure to persist has substantial ﬁnancial consequences
within the ﬁeld of osteoporosis management. This conclusion is
consistent with the evidence available from both observation
studies and modelling analyses in the US and UK health care
systems. Further work is warranted to review other disease
areas, and to further synthesise the data to provide an
estimated aggregate of the international cost of medication
non-compliance.
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OBJECTIVES: To assess the cost-effectiveness of an ongoing
osteoporosis screening campaign in Belgian women aged from
50 to 69 years. METHODS: A cost-effectiveness analysis was
performed using a decision tree analysis and a microsimulation
Markov model. We compared the screening campaign versus no
intervention. Screening campaign consisted of quantitative
ultrasound screening by mobile units. For all individuals having
a positive result, three possibilities are observed: no follow-up,
direct treatment or screening with DXA (dual energy X-ray
absorptiometry). Most of the individuals having a positive
DXA result received Alendronate therapy. Sensitivity analyses
and simulations were based on model parameters (discount
rates, fracture costs, fracture risks, fracture disutility, mortality
excess and treatment speciﬁcities), characteristics of screening
campaign (screening efﬁcacy, prevalence of osteoporosis and
screening cost), number of clinical risk factors and persistence
level. RESULTS: In the base case (with 100% persistence), the
cost per QALY gained for the screening strategy was €44,927.
Sensitivity analyses showed that this value was affected by per-
sistence level (€81,921 for realistic persistence). The efﬁciency
greatly improved if we only screen individuals with one clinical
risk factor (€23,265) or more (from €15,377 for two clinical
risk factors to cost-saving for four clinical risk factors). We also
showed that pre-screening using quantitative ultrasound was
more efﬁcient than universal DXA screening if the cost of quan-
titative ultrasound was less than €14.8 per patient screened.
CONCLUSION: The base case result was near to threshold
value of €45,000 per QALY gained. Consequently, it was dif-
ﬁcult to interpret the results and to qualify the campaign efﬁ-
ciency. Our recommendations to improve it are to target
screening on individuals with one or more clinical risk factors,
to generalize DXA for all individuals having a positive quanti-
tative ultrasound result, to treat all individuals having a posi-
tive DXA result and to improve compliance and adherence to
therapy.
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OBJECTIVES: To compare effectiveness, medical costs and cost-
effectiveness of zoledronic acid, one single yearly infusion, versus
usual care in post-menopausal osteoporosis in France, taking
into account compliance proﬁles. METHODS: Twelve simula-
tion based models were built to investigate 3 types of fractures:
vertebral (VF), non-vertebral (NVF) and hip (HF), comparing 2
groups: zoledronic acid and usual care. Two effectiveness
assumptions have been tested to handle the issue of clinical trial
population heterogeneity: 1) speciﬁc agent effectiveness values,
and 2) same standard effectiveness range of values for all active
agents. Direct medical costs include drug costs, medical visits,
monitoring and fracture medical management. Compliance has
been integrated into the model with the assumption that non-
compliant patients have the placebo effectiveness range of values.
Conservative compliance range of rates for active agents has been
expressed in accordance with the literature and expert opinion,
from 40% to 60% for oral drugs and from 50% to 100% for
Zoledronic acid single yearly infusion. A full probabilistic sensi-
tivity analysis has been carried out to generate costs, effectiveness
and cost-effectiveness over 3 years, with conﬁdence intervals.
Statistical tests were performed to calculate potential signiﬁcant
differences. RESULTS: Using the second assumption (2), the
zoledronic acid strategy leads to less vertebral, non-vertebral
and hip fractures than usual care: (88.0% vs. 85.7%,
89.4% vs. 88.2% and 97.2% vs. 95.4%) respectively, (p <
0.001). Zoledronic acid generates lower total medical costs
versus usual care in all types of fracture (p < 0.001): 944€ vs.
995€ (VF), 1164€ vs. 1245€ (NVF) and 1156€ vs. 1261€ (HF).
CONCLUSION: Zoledronic acid is the dominant strategy,
regardless of fracture type or effectiveness assumptions. A simu-
lation modeling approach seems appropriate to investigate
various effectiveness values from heterogeneous clinical trials.
Isolating the compliance effect allows us to conﬁrm the added
value of a once yearly infusion of zoledronic acid 5 mg.
POS8
COMPARISON OFTHE COST-EFFECTIVENESS OF
ZOLEDRONIC ACID 5 MG FORTHE MANAGEMENT OF
POST-MENOPAUSAL OSTEOPOROSIS INTHE UK SETTING
Olson M1, Brereton N2, Huels J1, Roberts D3,Akehurst R2
1Novartis Pharma AG, Basel, Switzerland, 2University of Shefﬁeld,
Shefﬁeld, UK, 3Novartis Pharmaceuticals UK Ltd, Frimley, UK
OBJECTIVES: To evaluate the cost effectiveness of zoledronic
acid 5 mg once yearly compared to the leading branded com-
pounds in the UK, i.e. Fosamax once weekly, Actonel once
weekly, Bonviva once monthly, and Protelos once daily in
patients with postmenopausal osteoporosis. METHODS: The
cost effectiveness model applied tracks the model NICE used in
their appraisal document for the cost effectiveness of treatments
of osteoporosis in postmenopausal women at increased risk of
fracture. Lifetime costs and quality adjusted life years (QALYs)
were calculated assuming ﬁve years of treatment. Relative risks
of fracture protection were obtained from the HORIZON-PFT
trial for zoledronic acid 5 mg, meta-analyses from NICE reviews
Abstracts A395
for Fosamax, Actonel, and Protelos, and from the European label
for Bonviva. Costs of fractures were taken from the NICE review
of Protelos and costs of the medications were taken from the
MIMS listing from February, 2007. Utilities were obtained from
the literature (Kanis, OI 2004;15:20–6). RESULTS: For patients
50 and older, zoledronic acid 5 mg dominated (i.e., more effective
at lower cost) branded Fosamax, Actonel, and Protelos. For
patients 70 and older, zoledronic acid 5 mg dominated Bonviva
while at lower ages, it was more cost effective (ICER < 3,100/
QALY gained). Incremental cost effectiveness ratios against
calcium plus vitamin D for zoledronic acid 5 mg were around or
below the usually referenced threshold of 20 K/QALY, ranging
from 20,582/QALY at age 50 to 7,418/QALY at age 80.
For the other treatments, the ranges of ICER versus calcium
plus vitamin D were 36,095/QALY to 12,542/QALY for
Fosamax, 53,916/QALY to 22,261/QALY for Actonel,
50,840/QALY to 26,179/QALY for Protelos, and 158,479/
QALY to 57,583/QALY for Bonviva. CONCLUSION: For
patients aged 50 and above with a BMD T-score of -2.5,
zoledronic acid 5 mg either dominates or is cost-effective com-
pared with Fosamax, Actonel, Protelos, and Bonviva.
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OBJECTIVES: The purpose of the study was to assess the cost-
effectiveness of the recombinant human PTH (1–34) (teri-
paratide) (Forsteo, Eli Lilly) and recombinant human PTH
(1–84) (Preotact, Nycomed) in subjects with similar clinical
characteristics to patients with osteoporosis in normal Swedish
clinical practice. METHODS: The cost-effectiveness was esti-
mated in an existing Markov cohort osteoporosis model using
6-month cycles and a lifetime horizon. The model was popu-
lated with Swedish epidemiological and economic data. To
reﬂect the normal clinical practice, the simulated subjects cor-
responded to the Swedish cohort in the European Forsteo
Observational Study (EFOS) (mean age 72 years, total hip
T-score -2.7, 3.5 prevalent vertebral fractures). The cost per
QALY gained of both teriparatide and PTH (1–84) was esti-
mated compared to no treatment based on efﬁcacy estimates
from phase III pivotal clinical trials of each drug. For teri-
paratide, the risk reduction for new vertebral fractures was
65% and for non-vertebral fragility fractures 53%, while PTH
(1–84) reduced the risk of vertebral fractures by 58% and
showed no difference in non-vertebral fracture risk reduction.
An indirect cost-effectiveness comparison between the two regi-
mens was also attempted. The annual drug cost of teriparatide
and PTH (1–84) in Sweden was €5241 and €4643, respectively.
Both treatment regimens were assumed to be given for 18
months per local reimbursement guidelines. The analysis took a
societal perspective excluding costs in added life years in the
base estimations. RESULTS: In the base case analysis excluding
the impact of hypercalcaemia the cost per QALY gained with
teriparatide and PTH (1–84) vs. no treatment was estimated at
€47,811 and €125,474, respectively. An indirect comparison
between the two treatments indicated teriparatide to be a domi-
nating alternative. CONCLUSION: This study suggests that,
based on the efﬁcacy estimates from pivotal clinical trials and
the Swedish cost of both drugs, teriparatide is a more cost-
effective treatment option than PTH (1–84).
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OBJECTIVES: To estimate the economic burden of patients with
osteoporotic hip fracture amongKoreanwomen.METHODS:All
claims records of Korean National Health Insurance for women
50 years of age or older with a diagnosis of hip fracture from 2002
to 2004 were identiﬁed. The ﬁrst 6-month period was set to be a
‘window period,’ such that patients were deﬁned as incident cases
if their ﬁrst record of fracture visit or admissionwas observed after
June 30, 2002. We excluded patients with multiple fractures,
patients with the records of high-cost diseases, such as cancer, and
patients without a record of a diagnosis or prescription for
osteoporosis. For each patient, we cumulated the claims amount
of the ﬁrst fracture visit or admission and follow-up treatments for
2 years after the incidence of fracture. Also, to investigate out-of-
pocket costs outside the health care institutions, face-to-face
interviews were conducted with 101 patients from 4 general
hospitals who had experienced a hip fracture at least 6 months
before the time of the interview. The total cost for fracture was the
sum of the direct health care costs, transportation costs for visits
to hospitals, and caregivers’ time cost spent hospital or outpatient
visits. RESULTS: A total of 22,247 osteoporotic hip fracture
patients were identiﬁed during 2.5 years. For the ﬁrst year of
fracture, patients had an average of 3.28 visits and 0.97 admis-
sions, whereas 0.35 visits and 0.02 admissions were recorded for
the second year. The 2-year cost was US$8,538 and increased
exponentially with age, $7,616 for 50–64 years old, $9,542 for
65–74, $10,077 for 75–84, and $10,118 for 85 or above. CON-
CLUSION: Exploring the economic burden of osteoporotic hip
fracture will motivate policy makers and clinicians to adopt
effective treatment options for osteoporosis to prevent the inci-
dence of fracture among elderly population.
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OBJECTIVES: To estimate hospital and facility costs resulting
from falls in long term care facilities (LTCFs). METHODS: The
study employed a non-randomized, before and after with com-
parison group design. Propensity scoring and matching were
used to control for baseline differences between fallers and non-
fallers. A multi-facility long-term care company provided data
from residents institutionalized between January 1, 2002 and
October 30, 2004. Data included Minimum Data Set (MDS)
observations, Resource Utilization Group (RUG) classiﬁcations,
and demographics. An index date was assigned to each resident
to identify pre-and post-periods. The index date was deﬁned as
the date of the ﬁrst fall for fallers. The index date was assigned to
non-fallers such that the time in the pre-period was equal for
fallers and non-fallers. Hospital costs were estimated from MDS
measures of the numbers of hospitalizations in each period and a
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